AIDS Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Tuberculosis Vaccine
Grant Received To Develop TB Vaccine Using CD1 Technology
August 23rd, 1999
Aquila Biopharmaceuticals, Inc., Framingham, Massachusetts, announced that it has been awarded a grant from the U.S. National Institutes of Health (NIH) to support the development of vaccines for tuberculosis (TB) based on the CD1 immune enhancement technology. The grant was awarded to Aquila under Phase II of the Small Business Innovation Research (SBIR) Program of the U.S. National Institutes of Allergy and Infectious Diseases (NIAID) branch of NIH, and provides $870,000 over a two year period. "Presentation of lipid antigens to the immune system using the CD1 platform represents a new approach to stimulating or regulating the immune system. ...
Source: AIDS Weekly (1999-08-23)
|
